Boulgourdjian E M, Martínez A S, Ropelato M G, Heinrich J J, Bergadá C
Division of Endocrinology, CEDIE, Hospital de Niños Dr Ricardo Gutiérrez, Buenos Aires, Argentina.
Acta Paediatr. 1997 Nov;86(11):1261-2. doi: 10.1111/j.1651-2227.1997.tb14858.x.
To assess the efficacy of treatment with oral desmopressin (DDAVP), 20 patients, aged 5-20 y, with central diabetes insipidus were studied during 3 d of hospitalization and for 3 months at the outpatient clinic. At baseline the median rate of diuresis was 12.7 ml kg-1 h-1. Urinary output decreased significantly under treatment with an increase in urinary osmolality, normalization of plasma osmolality and absence of nocturia. Patients were discharged from hospital with a median dose of 500 micrograms d-1 (100-1200 micrograms d-1). An adjustment in dosage was necessary in seven patients during follow-up, resulting in a final dose of 600 micrograms d-1. Body weight and DDAVP doses (r = 0.75, p = 0.001) and body surface and DDAVP doses (r = 0.72, p < 0.001) were significantly correlated. The average dosage was 474 +/- 222 micrograms m-2 d-1 (mean +/- SD). The oral DDAVP treatment remained effective during the 3 months of follow-up. This therapy offers an alternative for the treatment of central diabetes insipidus in children.
为评估口服去氨加压素（DDAVP）的治疗效果，对20例年龄在5至20岁的中枢性尿崩症患者在住院3天期间及门诊随访3个月进行了研究。基线时，利尿中位数速率为12.7 ml·kg⁻¹·h⁻¹。治疗期间尿量显著减少，尿渗透压升高，血浆渗透压恢复正常且无夜尿。患者出院时的中位剂量为500微克/天（100 - 1200微克/天）。7例患者在随访期间需要调整剂量，最终剂量为600微克/天。体重与DDAVP剂量（r = 0.75，p = 0.001）以及体表面积与DDAVP剂量（r = 0.72，p < 0.001）显著相关。平均剂量为474 ± 222微克·m⁻²·天⁻¹（均值 ± 标准差）。口服DDAVP治疗在3个月的随访期间持续有效。该疗法为儿童中枢性尿崩症的治疗提供了一种替代方案。
